| Tums, Calcium Carbonate 500 mg
Tums E-X, Calcium Carbonate 750 mg
Tums ULTRA, Calcium Carbonate 1000 mg
Tums: Do not take more than 15 tablets in a 24-hour period or use the maximum dosage of this product for more than 2 weeks, except under the advice and supervision of a physician. If symptoms persist for 2 weeks, stop using this product and see a physician. Keep this and all drugs out of the reach of children.
Dosage and Administration:
DIRECTIONS: Chew 2 tablets twice daily.
| Signs: paresthesias, tetany (especially carpopedal spasm), lethargy, confusion, seizures, Trousseau’s sign (carpal spasm occurring after the occlusion of the brachial artery with a blood pressure cuff for 3 minutes), Chvostek’s sign (contraction of the facial muscle in response to tapping the facial nerve anterior to the ear), QT prolongation.
Normal values: Total Calcium: 8.4-10.2 mg/dl (2.1-2.6 mmol/L). Ionized Calcium: 3.8-5.3 mg/dl (0.95-1.35 mmol/L). Protein binding: Moderate, approximately 45% in plasma.
1. Correct for hypoalbuminemia: If albumin is < 2, check ionized Ca++. Note that alkalosis augments Ca++ binding to albumin, decreasing the amount of ionized (effective) Ca++ and increasing severity of symptoms at a given level.
Oral: CaCO3 500-1000 mg TID between (after) meals (to maximize absorption). Also consider vitamin D in patients with renal failure.
IV: max 10 mEq/hour. Symptomatic hypocalcemia (See signs above) — Patients should be treated immediately. Many patients have symptoms when their serum ionized calcium conc is < 2.8 mg/dL (0.7 mmol/L), or their serum total calcium conc (corrected) is ~ 7 to 7.5 mg/dL (1.8 mmol/L).
The most appropriate treatment, unless hypomagnesemia is documented, is intravenous calcium, in the form of 100 to 200 mg (2.5 to 5 mmol) of elemental calcium (1 to 2 grams of calcium gluconate) in 10 to 20 minutes. The calcium should not be given more rapidly, because of the risk of serious cardiac dysfunction, including systolic arrest. Such infusions do not raise the serum calcium concentration for more than two to three hours, and therefore should be followed by a slow infusion of calcium. The dose should be 0.5 to 1.5 mg/kg per hour. Either 10% CaGluc (93 mg [2.25 mmol] elemental Ca++/ 10 ml amp) or 10% CaCL (272 mg [6.75 mmol] elemental Ca++/ 10 ml amp) can be used, with the following recommendations: The calcium should be diluted in dextrose and water or saline, because concentrated calcium solutions are irritating to veins. Calcium gluconate is usually preferred to calcium chloride because it is less likely to cause tissue necrosis if extravasated.
Hypocalcemia (dose depends on clinical condition and serum calcium level): Dose expressed in mg of elemental calcium: 1-2 grams or more/day in 2-4 divided doses. Antacid: Dosage based on acid-neutralizing capacity of specific product – generally, 1-2 tablets or 5-10 ml every 2 hours. Maximum: 7000 mg calcium carbonate per 24 hours.
Calcium / Vitamin D combinations:
Caltrate 600 + D (Vitamin D 200 IU + Calcium Carbonate 600mg): one tablet twice daily with food. Os-Cal 500 + D (Vitamin D 200 IU + Calcium Carbonate 500mg): Directions: One tablet two to three times a day with meals.
Dietary Reference Intake: (Dosage is in terms of elemental calcium):
19-50 years: 1000 mg/day. (e.g. 1.25 g CaCO3 bid) or (625 mg qid etc).
>51 years: 1200 mg/day.
Dosage form Elemental Ca++
Calcium Carbonate 500 mg chewable tabs ( Tums®) 200 mg
Calcium Carbonate 650 mg tablets 260 mg
Calcium Carbonate 1250 mg tablets OsCal 500® 500 mg
Calcium Carb 250 mg + Vit D 125 IU/tablet OsCal 250 +D® 100 mg
Calcium Glubionate syrup 1.8 gm/5ml NeoCalglucon® 115 mg/5ml
Calcium acetate (Phos Lo®) is available for phosphate binding and not calcium replacement in patients with renal insufficiency since its calcium absorption is poor.
USUAL DOSE: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). *Absorption is variable and depends on PTH, Vitamin D, and gastric pH.
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer